Option chain shows key data for Marker Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Marker Therapeutics.

Marker Therapeutics (NASDAQ:MRKR) Stock, Option Chain

Marker Therapeutics

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Biotech

News

Health Care

General

MRKR

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. 

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Movers

Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter 

Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?

Penny Stocks

Small Cap

Intraday Update

Markets

Trading Ideas

AAMC

AVTA

AXLA

BFLY

BGLC

BGNE

BOWL

CING

CRNX

CXAI

ELUT

FLWS

GRNT

HKIT

IMPL

KXIN

LPTV

MGTA

MULN

NEPT

NUWE

PODC

PSTV

PUYI

SGMA

SMRT

SPCE

SWIN

TNON

TSLA

Hostess Brands, Inc. - Class A Common Stock

TWNK

VIRC

WLGS

YOSH

Gainers


	Crinetics Pharmaceuticals, Inc.  (NASDAQ: CRNX) jumped 76% to $28.13 after the company&#39;s once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.


Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Marker Therapeutics Inc

Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) reported fourth-quarter financial results Wednesday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/01/b43145255/discover-financial-services-reports-fourth-quarter-2024-net-income-of-1-3-billion-or-5-11-per-dilu">of the report</a>.
<ul>
<li>Q4 Revenue: $4.76 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $4.46 billion</li>
</ul>
<ul>
<li>Q4 EPS: $5.11, versus estimates of $3.58</li>
</ul>
In the digital banking segment, Discover ended the period with total loans of $121.1 billion, down 6% year-over-year. Net interest income for the quarter grew by&nbsp;5%&nbsp;year-over-year, driven by net interest margin expansion. Non-interest income increased&nbsp;68% year-over-year and total operating expenses climbed 4% year-over-year.
Payment services pretax income increased 37% year-over-year primarily due to volume growth and timing of incentives. Payment services volume was up&nbsp;4%&nbsp;compared to the prior year&#8217;s quarter.
&#8220;Discover&#8217;s&nbsp;fourth quarter&nbsp;results capped off a successful 2024 as loan growth, margin expansion, and credit improvement led to strong financial performance,&#8221; said Michael Shepherd, Discover&#8217;s interim CEO and president. 
&#8220;It was a transformative year for our business as we announced our pending merger with Capital One, exited student lending, and enhanced our risk management and compliance programs. These actions position us well for the future.&#8221;
See Also: <a href="https://www.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">Happy Birthday S&amp;P 500 SPY ETF! If You Invested $1,000 In SPY At Launch, Here&#8217;s How Much You&#8217;d Have Today</a>
Discover&#8217;s board declared a quarterly cash dividend of 70 cents per share, payable on March 6 to shareholders of record as of Feb. 20. 
Management will further discuss the quarter on a conference call with analysts and investors slated for 8 a.m. ET Thursday morning.
DFS Price Action: <a href="http://benzinga.com/quote/dfs">Discover shares</a> were up 1.24% after-hours on Wednesday, trading at $199.95 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Discover.

Earnings

After-Hours Center

Discover Delivers Q4 Earnings Beat, Revenue Beat: The Details

Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) has outperformed the market over the past 5 years by 8.35% on an annualized basis producing an average annual return of 21.51%. Currently, Ingersoll Rand has a market capitalization of $37.98 billion. 
Buying $1000 In IR: If an investor had bought $1000 of IR stock 5 years ago, it would be worth $2,729.72 today based on a price of $94.23 for IR at the time of writing.
<h3>Ingersoll Rand's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737587710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares closed down Wednesday, due to a<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43142275/bitcoin-ethereum-xrp-dogecoin-reel-downwards-but-trader-hints-at-bitcoin-god-candle-loading"> decline in Bitcoin's (CRYPTO: BTC/USD) price</a>, which dropped 1.73% to $104,313.65.
What To Know: Bitcoin transaction volume over $100,000 decreased by 15%, while netflows dropped 307%, signaling a possible cooling of market activity. Over $161 million in liquidations occurred in the past 24 hours, which put additional pressure on the market. 
While BlackRock clients facilitated the purchase of $600 million in Bitcoin via an ETF, market sentiment remains cautious due to the nature of these transactions.
Bitcoin's liquidity is concentrated between $96,000 and $111,000, with support levels between $88,000-$95,000. If these levels fail, Bitcoin could drop further, potentially impacting MicroStrategy's stock as well. 
Despite the short-term volatility, Bitcoin&#8217;s overall bullish trend remains intact as long as it stays above $58,000, which provides some stability for MicroStrategy.
Why It Matters: For MicroStrategy, the company's heavy exposure to Bitcoin potentially means its stock is especially sensitive to Bitcoin's price. The company also recently received shareholder approval for a proposal to increase its share count, which could lead to more Bitcoin purchases in the future. 
MSTR Price Action: Microstrategy shares closed Wednesday down 3.03% at $377.31, according to<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22165820/Screenshot-2025-01-22-at-16.57.45-1024x521.png" alt="" class="wp-image-745617" style="width:502px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22165820/Screenshot-2025-01-22-at-16.57.45-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22165820/Screenshot-2025-01-22-at-16.57.45-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22165820/Screenshot-2025-01-22-at-16.57.45-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22165820/Screenshot-2025-01-22-at-16.57.45.png 1437w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43138667/donald-melania-trump-meme-coins-are-a-personal-brand-play-says-anthony-pompliano">Donald, Melania Trump Meme Coins Are A Personal Brand Play, Says Anthony Pompliano</a></li>
</ul>
Image Via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

MicroStrategy Shares Are Down With Bitcoin Today: What's Going On?

Wall Street has shown time and again that it's resilient enough to withstand a variety of challenging macroeconomic conditions.&nbsp;
From the <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">high inflation</a> barrage of 2022 to a 5.5% peak in interest rates beginning in 2023, the S&amp;P 500's recovery to new all-time highs is a bullish signal. But what impact could the prospect of fewer rate cuts in 2025 have on the overall health of the market?&nbsp;
January 2025 saw Fed officials indicate that they <a href="https://www.morningstar.co.uk/uk/news/258864/will-the-us-fed-raise-interest-rates-in-2025.aspx#:~:text=Fed%20officials%20indicated%20they%20now,cuts)%20in%20their%20September%20projections." target="_blank" rel="noreferrer noopener">now expect two rate cuts</a> amounting to a half point throughout the year ahead. The news compounded the S&amp;P 500's steady decline in what's set to be a period of economic uncertainty for markets as the unpredictable President-elect Donald Trump approaches his second term in the White House. 
As recently as September, officials were anticipating a full percentage point of cuts throughout 2025 at a crucial time for Wall Street firms seeking to take advantage of lower borrowing costs to embrace the ongoing AI boom surrounding key sectors.&nbsp;
Lower interest rates are generally bullish for US firms because the lower cost of borrowing helps to facilitate more spending, investing, and hiring strategies.&nbsp;
Although US Bank data suggests that equity investors appear to be <a href="https://www.usbank.com/investing/financial-perspectives/market-news/how-do-rising-interest-rates-affect-the-stock-market.html" target="_blank" rel="noreferrer noopener">more focused</a> on factors like the wider economy and corporate earnings ahead of interest rates, a higher-for-longer environment could profoundly impact the growth of the most innovative players throughout US markets in 2025. This could have a domino effect on the growth of innovation throughout the AI sector and strong-performing markets in recent years. 
<h2 class="wp-block-heading">Keeping the Good Times Rolling&nbsp;</h2>
Tech stocks populate around one-third of the S&amp;P 500 index, and recent advances in AI and the hype surrounding innovations throughout the sector have played a key role in enabling Wall Street to shake off jitters related to historically high inflation and interest rate hikes in recent years.&nbsp;
Shares in leading AI stocks like Nvidia and Broadcom, which rallied 171% and 108% respectively in 2024, have helped to sustain the S&amp;P 500's outperformance, with the index surging 23.31% throughout the year with 57 record closes.&nbsp;
However, in the 21st Century, the average gain of the S&amp;P 500 is closer to 10% per year. It's this contrast that underlines the importance of the AI boom to Wall Street's health.&nbsp;
JPMorgan data has laid bare the historical parallels between Federal Reserve rate cuts and bullish sentiment on Wall Street. Since 1980, <a href="https://www.jpmorgan.com/insights/markets/top-market-takeaways/tmt-rate-cut-breakdown-what-you-need-to-know-now" target="_blank" rel="noreferrer noopener">five of the best 10 years</a> for the S&amp;P 500 happened when the Fed was cutting rates without a recession. Additionally, the Fed has cut rates 12 times when the index was within 1% of its all-time high, and in all 12 cases, the market was higher one year later–boasting a median return of 15%. 
Because the immediate effect of rate cuts involves a reduction in borrowing costs, these dovish reversions generally <a href="https://www.linkedin.com/pulse/what-fintech-industry-can-expect-from-rate-cut-later-year-oslgc#:~:text=Impact%20on%20Capital%20and%20Investment,wave%20of%20innovation%20and%20expansion.">improve consumer spending</a> as well as investment in innovation. This paves the way for cheaper access to capital and far stronger growth prospects.&nbsp;
At a time when the generative AI boom is moving from its hype phase to its implementation phase, this access to spending is imperative for the sustainability of Wall Street's brightest tech startups, and a more hawkish stance from the Fed could stifle the scaling up of artificial intelligence adoption.&nbsp;
<h2 class="wp-block-heading">Could Higher Rates Bring Growth?&nbsp;</h2>
Other high-growth industries like fintech could present solutions to consumers during a higher-for-longer interest rate environment that helps to keep stocks within the sector higher amid the uncertainty.&nbsp;
Although higher rates will stifle consumer appetite for borrowing, innovations <a href="https://www.benzinga.com/fintech/25/01/42818294/how-fintech-must-evolve-to-meet-the-needs-of-techs-new-wealth" target="_blank" rel="noreferrer noopener">within fintech like open banking</a> and buy now pay later (BNPL) could empower consumers to navigate the challenging economic climate. 
While open banking can help to promote financial management and literacy across various banking, investing, and saving apps, the <a href="https://www.eposnow.com/us/resources/payment-trends/#buy-now-pay-later" target="_blank" rel="noreferrer noopener nofollow">emerging BNPL trend</a> paves the way for access to borrowing for essential purchases that are usually interest-free. 
With this in mind, we could see the fintech landscape continue to grow as a solution to high interest rates while other major tech industries are hampered by higher costs during their scaling process.&nbsp;
<h2 class="wp-block-heading">Wall Street's Trump Card</h2>
Donald Trump's second term in the White House is sure to influence the performance of US markets alongside interest rates throughout 2025.&nbsp;
Concerns over the President-elect's tariffs and a stronger US Dollar, both of which could be inflationary, may significantly impact the Federal Reserve's stance on interest rates throughout the year.&nbsp;
Should a strengthening dollar begin to <a href="https://www.ig.com/au/trading-strategies/Why-US-rate-cuts-in-2025-could-surpass-current-expectations-250108" target="_blank" rel="noreferrer noopener">impact the ability of US manufacturers</a> and exporters to trade internationally, we could see the Fed cut rates to maintain a level of competitiveness across global markets. 
On the flip side, Trump's stance on deregulation could be such a catalyst for growth that it <a href="https://www.businessinsider.com/federal-reserve-fed-interest-rates-analyst-reaction-wall-street-stocks-2024-12" target="_blank" rel="noreferrer noopener nofollow">pushes yields higher</a> and prompts a Federal Reserve intervention, according to Jochen Stanzl, chief market analyst at CMC Markets. It's for this reason that early inflation data surrounding Trump's Presidency will be crucial for the future of rate cuts. 
<h2 class="wp-block-heading">What to Expect in 2025</h2>
The sheer power of the ongoing AI boom means that we're likely to see a high level of resilience in the S&amp;P 500 even in the most unpredictable of market circumstances. However, all bets are off when it comes to the rate cuts we're likely to see throughout the year.&nbsp;
While the Fed anticipates two cuts in 2025, Trump's arrival in the White House will be the deciding factor for the direction that both interest and <a href="https://www.benzinga.com/topic/inflation" target="_blank" rel="noreferrer noopener">inflation</a> take in the new year. 
As a hedge against the uncertainty, there may be more value in fintech moving forward, but the best approach for investors is to avoid resting on laurels and to continue to analyze emerging market and inflation data.&nbsp;

Macro Economic Events

Bonds

Measuring the Uneven Impact of Weakening Rate Cut Forecasts on Wall Street in 2025

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are falling in Wednesday&#8217;s after-hours session after the space-based cellular broadband network company announced a <a href="https://www.benzinga.com/pressreleases/25/01/b43145116/ast-spacemobile-announces-proposed-private-offering-of-400-0-million-of-convertible-senior-notes-d">proposed private offering</a>.
What Happened: After the market close on Wednesday, AST SpaceMobile announced plans to offer $400 million worth of convertible senior notes due 2032 in a private offering to institutional investors. 
The company said it also intends to grant the initial purchasers a 13-day period to purchase up to an additional $60 million of the notes. 
AST SpaceMobile plans to use a portion of the net proceeds to pay the cost of capped call transactions. The remaining proceeds will be used for working capital and other general corporate purposes. 
AST SpaceMobile last reported <a href="https://www.benzinga.com/general/space/24/11/41994523/ast-spacemobile-misses-q3-earnings-expectations-announces-new-launch-service-agreements">earnings</a> in November, ending the period with $518.9 million in cash, cash equivalents and restricted cash.
AST Price Action: AST SpaceMobile shares were down 13.74% in after-hours, trading at $19.41 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43144858/sp-500-hits-fresh-records-at-6100-as-strong-earnings-trumps-ai-wager-fuel-bull-run">S&amp;P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump&#8217;s AI Wager Fuel Bull Run</a></li>
</ul>
Photo: Courtesy of AST SpaceMobile.

SPACE

Offerings

ASTS

AST SpaceMobile Stock Is Tumbling Wednesday: What's Going On?

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) has outperformed the market over the past 5 years by 31.79% on an annualized basis producing an average annual return of 44.95%. Currently, CrowdStrike Holdings has a market capitalization of $93.11 billion. 
Buying $1000 In CRWD: If an investor had bought $1000 of CRWD stock 5 years ago, it would be worth $6,510.16 today based on a price of $378.00 for CRWD at the time of writing.
<h3>CrowdStrike Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737586813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRWD

$1000 Invested In CrowdStrike Holdings 5 Years Ago Would Be Worth This Much Today

UBS analyst John Hodulik maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $1040 to $1150.

Price Target

Analyst Ratings

NFLX

UBS Maintains Buy on Netflix, Raises Price Target to $1150

KULR Technology Group Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) shares are trading higher on Wednesday after announcing a groundbreaking <a href="https://www.benzinga.com//node/43126655">pyrolytic carbon electrode</a> developed in collaboration with Scripps Research Institute&#8217;s Baran Lab.
The Details: The electrode is key for the synthetic organic electrochemistry field, a sector integral to the production of pharmaceuticals. Compared to traditional carbon materials, KULR described the electrode as more cost-effective, durable and reusable. 
&#8220;KULR&#8217;s expertise in carbon materials, combined with the innovative vision of Scripps Research&#8217;s Baran Lab, has resulted in a truly transformative material for synthetic chemistry,&#8221; said Michael Mo, CEO of KULR Technology. 
&#8220;We are excited to bring this technology to market, where it has the potential to redefine how we approach large-scale chemical synthesis.&#8221;
<h1 class="wp-block-heading">How To Buy KULR Technology Stock</h1>
By now you're likely curious about how to participate in the market for KULR Technology — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. For example, some stock, such as Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of KULR Technology, which was trading at $2.65 at some point on Wednesday, $100 would buy 37.74 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
KULR Price Action: KULR stock closed Wednesday up 6.89% at $2.56, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
See Also: • <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43141388/people-buy-bitcoin-as-prayer-for-a-better-tomorrow-cnn-pundit-van-jones-says-as-former-harris-aide-slams-trump-as-grifter-in-chief">People Buy Bitcoin As &#8216;Prayer For A Better Tomorrow, CNN Pundit Van Jones Says As Former Harris Aide Slams Trump As &#8216;Grifter In Chief&#8217;</a>
Photo: Gorodenkoff via Shutterstock

KULR

What's Going On With KULR Technology Shares Wednesday?

Welcome, my friends, to what I am calling the Age of Uncertainty. This little catchphrase is going to be sticking around for at least the next four years. As I write this, Donald Trump has just taken office.
It's the first week of his Presidency and the start of his administration is just about what we expected with a few surprises thrown in for good measure: new takes on energy, trade, immigration, and much more.
Let us dive into what is happening and what it all means for your money.
<h2 class="wp-block-heading">Trump&#8217;s Opening Moves</h2>
Contrary to the predictions of many in the financial world, Trump came out of the gate a bit softer on China. No immediate tariffs or trade wars, just an announcement that the United States trade policy will be reviewed and some suggestion and indication of what is coming down the pike.
Trump has touched on familiar themes such as immigration and border security. One hot button issue was his executive order aimed at ending birthright citizenship. While the abuse of this system is real (indeed, even wealthy families use it to get dual citizenship for their kids), this fight will undoubtedly end up in the courts. Changing a constitutional clause is not exactly a walk in the park. But hey, I am sure Trump has got it all figured out.
On the border, his halt on catch and release policies is likely to boost business for companies such as GEO Group. They own jails on the United States Mexico border, and with Trump&#8217;s border policies in play, it is looking good for them.
<h2 class="wp-block-heading">Energy and Trade</h2>
Trump&#8217;s &#8220;drill, baby, drill&#8221; stance is music to the ears of those invested in oil and gas infrastructure. With plans to explore and produce energy on federal lands and waters, kill offshore wind leases, and remove restrictions on drilling in Alaska, the energy sector is poised for growth. We own energy royalties and non-operator ownership interests in oil wells, and every uptick in production is a win for us. Trump also promised a sweeping trade overhaul, with reviews of agreements with China, Canada, and Mexico. The potential for tariffs on our neighbors could shake things up, but it is all still uncertain.
<h2 class="wp-block-heading">Inflation, Debt, and the Economy</h2>
Let us address the elephant in the room: inflation.
It is still here, it is sticky, and it is not going anywhere soon. Sure, we have seen it drop from over 9% to around 3%, but do not expect a rollback on prices anytime soon. Food and energy costs remain stable for now, but any disruption could quickly change that.
As for government spending, we are on a never-ending roller coaster. Infrastructure, energy, semiconductors, and rehoming critical industries all require and you guessed it and government spending. Debt levels are troubling, but the United States can still sell its bonds easily, so a debt crisis is not imminent. Consumers and corporations, meanwhile, are in pretty good shape. Debt to service ratios and balance sheets look strong, which is good news as we enter this new administration.
[Our tools and insights highlight stocks set to move and pinpoint the biggest earnings catalysts. Get actionable alerts the moment earnings break – so you can act first. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=WebRD-0123&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">Get My Alerts.</a>]
<h2 class="wp-block-heading">Why Asset Based Value Investing Works</h2>
In an environment like this, asset-based value investing shines. Here is why: when you invest in assets with intrinsic value, you are anchoring your portfolio to something tangible. Whether it is real estate, energy infrastructure, or even royalty streams, these investments are backed by physical or financial assets that generate real cash flow. This approach reduces reliance on market sentiment and speculative price movements.
For individual investors, this means you are not just betting on a hot stock or the latest trend. You are buying into assets where you can evaluate the downside risk with clarity. In uncertain times, this focus on tangible value and cash flow provides a much-needed margin of safety. Best of all, asset-based investments often come with the added bonus of inflation protection. Real assets such as property and energy infrastructure tend to appreciate over time, especially when inflation rears its head.
By prioritizing assets that are undervalued relative to their net asset value, you are setting yourself up for long term success. It is not flashy, but it works and it has worked for decades. In the Age of Uncertainty, asset-based value investing is a strategy that does not just survive; it thrives.
<h2 class="wp-block-heading">Why Buying Below Book Value is a Winning Strategy</h2>
Let us talk numbers. Historical data shows that buying stocks below book value often leads to extraordinary returns. Take a look at the annual returns for undervalued stocks. In years where investors focused on buying below book value, returns like 98.94% in 2003 and 95.19% in 2004 were achieved. Even in less spectacular years, returns consistently outperformed broader market indices.
Why does this work? Because buying below book value means you are acquiring assets at a discount. It is like buying a dollar for fifty cents. When market conditions normalize or improve, these undervalued stocks have the potential to surge, as their intrinsic value becomes recognized. This strategy aligns perfectly with asset-based value investing, where the focus is on tangible assets and strong fundamentals.
In volatile times, this approach gives investors a margin of safety. You are not just speculating on growth; you are investing in real, measurable value. And as history shows, the payoff can be remarkable. So, whether it is real estate, energy infrastructure, or beaten down stocks trading below book value, the principle remains the same: buy quality assets at a discount and watch them appreciate.
<h2 class="wp-block-heading">Using a Deep Value Approach to Real Estate Investing</h2>
Let us take a closer look at why a deep value approach to real estate investing is a game changer. The idea is simple but powerful: buy properties or real estate investment trusts (REITs) at prices well below their intrinsic or net asset value (NAV). This strategy works particularly well during times of market dislocation or uncertainty, when fear and volatility create opportunities to scoop up high quality assets at bargain prices.
By focusing on deep value, you are not just buying properties; you are buying into cash flow streams and tangible assets that are often mispriced by the market. For instance, Class A office properties or medical office buildings might be trading at discounts due to temporary concerns. However, their long-term fundamentals, such as high occupancy rates and reliable tenants, remain intact. By purchasing these properties below NAV, you set yourself up for both strong cash flow and significant capital appreciation as the market recovers.
This approach also aligns with the concept of a margin of safety. When you buy below NAV, you are essentially building in a cushion against potential risks or market downturns. Even if the broader real estate market faces headwinds, your investments are better positioned to weather the storm and deliver returns. And let us not forget: inflation is a friend to real estate. As the cost of goods and services rises, so do rents and property values, further enhancing the appeal of deeply discounted real estate assets.
<h2 class="wp-block-heading">Why Real Estate?</h2>
Publicly traded real estate has outperformed almost every other asset class over the long term. REITs have delivered stellar returns since the 1970s, even beating private equity (unless you have got millions to invest in those exclusive funds). Wall Street will not tell you this because there is no money in it for them. But I am here to tell you: buying high quality real estate at attractive prices is one of the smartest moves you can make.
<h2 class="wp-block-heading">Final Thoughts</h2>
This Age of Uncertainty is going to be a wild ride. Trump&#8217;s policies could bring great opportunities or unforeseen challenges. What we do know is that investing in high quality real estate with strong cash flows and rock-solid financials is a strategy that works. It has weathered inflation, market crashes, and bad government policies before, and it will continue to do so.
If you are ready to grow your wealth or secure steady income, consider adding the Total Return or Income portfolios to your strategy. As always, we will be here, watching, monitoring, and most importantly, collecting cash.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?utm_source=WebRD-0123&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}">Get Pro-Level Earnings Insights Before the Market Moves</a>
Image via Cagkan Sayin on Shutterstock

Opinion

Your Investing Playbook for the Next Four Years

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 4.12% on an annualized basis producing an average annual return of 12.64%. Currently, Cigna has a market capitalization of $80.40 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 20 years ago, it would be worth $11,032.06 today based on a price of $289.04 for CI at the time of writing.
<h3>Cigna's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737585918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Stock In The Last 20 Years

Citigroup analyst Asiya Merchant maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Neutral and raises the price target from $160 to $165.

Citigroup Maintains Neutral on TE Connectivity, Raises Price Target to $165

He will remain an employee of the Company to provide transition support and fulfill additional responsibilities until the end of March.
&nbsp;
 &nbsp;

Management

MSFT

Christopher Young Informs Microsoft Of His Decision To Resign; He Will Cease To Serve As Executive Vice President, Business Development, Strategy, And Ventures, Effective Immediately - Filing

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 20 years by 3.62% on an annualized basis producing an average annual return of 12.14%. Currently, Arthur J. Gallagher has a market capitalization of $73.32 billion. 
Buying $100 In AJG: If an investor had bought $100 of AJG stock 20 years ago, it would be worth $998.30 today based on a price of $293.50 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737585104_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Arthur J. Gallagher Stock In The Last 20 Years

Guidance

Alaska Air Group Expects Q1 Adj EPS Of $(0.70) - $(0.50), Est $(0.70); Sees FY25 Adjusted EPS Of >$5.75 (Est $5.90)

Shares of electric vehicle (EV) stocks, including Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), are trading lower amid continued weakness following<a href="https://www.benzinga.com/trading-ideas/movers/25/01/43113872/rivian-lucid-shares-are-falling-today-whats-going-on"> significant policy changes announced</a> by President Donald Trump.
What To Know: The policy shifts involve revoking a 2021 executive order issued by former President Joe Biden, which set a non-binding target for 50% of new vehicles sold in the U.S. to be electric by 2030. 
Trump&#8217;s executive order not only eliminates this target but also freezes unspent funds from a $5 billion EV charging infrastructure program. Additionally, the administration plans to reassess emissions regulations requiring automakers to sell between 30% and 56% electric vehicles by 2032 to meet federal standards.
The new policies also raise the possibility of repealing the $7,500 federal tax credit for EV purchases. Furthermore, Trump has expressed intentions to challenge California's waiver, which mandates zero-emission vehicles by 2035 and has been adopted by 11 other states. This could add further uncertainty for EV manufacturers that rely on these mandates to drive adoption.
For Rivian, known for its electric trucks, SUVs and delivery vans, the potential repeal of tax credits and reduced funding for EV infrastructure could dampen demand for its premium-priced vehicles. Lucid, another emerging player in the EV market, faces similar challenges as it contends with reduced government incentives and infrastructure support, critical factors for its growth.
RIVN, LCID Price Actions: Rivian shares were down 4.51% at $12.69 and Lucid shares were down 6.64% at $2.67 at market close Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2" target="_blank" rel="noreferrer noopener">Benzinga Pro.</a>
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43141048/whats-going-on-with-freeport-mcmoran-fcx-stock-ahead-of-q4-earnings-report">What&#8217;s Going On With Freeport-McMoRan (FCX) Stock Ahead Of Q4 Earnings Report?</a></li>
</ul>
Photos: Shutterstock

Government

LCID

RIVN

EV Stocks Are Falling Today: What's Going On?

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.44 by 120.45 percent. This is a 223.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $3.53 billion which beat the analyst consensus estimate of $3.43 billion by 2.92 percent. This is a 38.43 percent increase over sales of $2.55 billion the same period last year.

Earnings Beats

Alaska Air Gr Q4 2024 Adj EPS $0.97 Beats $0.44 Estimate, Sales $3.53B Beat $3.43B Estimate

S&amp;P 500 constituent Apollo Global Management is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.&nbsp;

ARWR

Arrowhead Pharmaceuticals To Replace  Barnes Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On January 27

Immunoprecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) shares are moving higher on Wednesday after the company announced it developed a new class of GLP-1 therapies.
What To Know: The company revealed Wednesday the development of a new class of GLP-1 therapies, which are often used to manage type two diabetes or obesity, using its artificial intelligence (AI) technology, the LENS platform.
The AI-driven platform identifies unique evolutionary patterns in biological data to design and optimize therapeutics. By leveraging these insights, the LENS platform enables faster and more precise drug discovery and development.
&#8220;LENS continued breakthroughs underscore the unparalleled power of our HYFT patterns,&#8221; said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 
&#8220;These patterns, which only IPA possesses, are the key to unlocking unprecedented speed and precision in biologics research. LENS is not just accelerating development — it&#8217;s redefining the very process of therapeutic innovation.&#8221;
The AI-developed GLP-1 therapies are engineered to enhance effectiveness, extend durability and simplify patient use, with advancements such as reduced dosing frequency and streamlined manufacturing processes. The company is currently evaluating the viability of delivering these GLP-1-like therapies via a transdermal patch rather than injection.
IPA Price Action: Immunoprecise stock closed Wednesday up 30.73% at 64 cents. After-hours trading has it down 8.53% at 59 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/insights/analyst-ratings/25/01/43139936/assessing-unity-software-insights-from-8-financial-analysts">Assessing Unity Software: Insights From 8 Financial Analysts</a>
Photo: Romix Image via Shutterstock

Tech

What's Going On With ImmunoPrecise Antibodies Stock Wednesday?

GWRE

Guidewire Software To Replace Arrowhead Pharmaceuticals In S&P MidCap 400, Effective Prior To Opening Of Trading On January 27

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 5.83% on an annualized basis producing an average annual return of 17.41%. Currently, Caterpillar has a market capitalization of $193.28 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 10 years ago, it would be worth $462.18 today based on a price of $395.21 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737584114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

Press Releases

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Financing

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Announces $16.1 Million Private Placement

KRRO

PLRX

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aprea Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Equillium

Eterna Therapeutics

GlycoMimetics

Geovax Labs

HOOKIPA Pharma

iBio

IN8bio

Kairos Pharma

Longeveron

MEI Pharma

NKGen Biotech

NextCure

Pluri

Palatin Techs

Senti Biosciences

Tenax Therapeutics

Ladenburg Thalmann

Roth Capital

Comments

Marker Therapeutics

Marker Therapeutics (MRKR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga